ID

44602

Description

A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1); ODM derived from: https://clinicaltrials.gov/show/NCT02265237

Link

https://clinicaltrials.gov/show/NCT02265237

Keywords

  1. 6/3/20 6/3/20 -
  2. 9/27/21 9/27/21 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

September 27, 2021

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Hepatitis C Virus NCT02265237

Eligibility Hepatitis C Virus NCT02265237

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
subjects must meet one of the following:
Description

Inclusion criteria Quantity Fulfill

Data type

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C1550543
treatment-naive (subject has never received antiviral treatment for hepatitis c infection) or for arms a, b, and c:
Description

Therapy naive | Antiviral Therapy Absent Hepatitis C | Protocol Arm Roman letter

Data type

boolean

Alias
UMLS CUI [1]
C0919936
UMLS CUI [2,1]
C0280274
UMLS CUI [2,2]
C0332197
UMLS CUI [2,3]
C0019196
UMLS CUI [3,1]
C1522541
UMLS CUI [3,2]
C0439102
treatment experienced (prior null responders, partial responders or relapsers to ifn/rbv)
Description

Therapy Received | Interferon | Ribavirin | Therapy non-responder | Partial responder to therapy | Relapse

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1514756
UMLS CUI [2]
C3652465
UMLS CUI [3]
C0035525
UMLS CUI [4]
C0919875
UMLS CUI [5]
C1740822
UMLS CUI [6]
C0035020
for arm d:
Description

Protocol Arm Roman letter

Data type

boolean

Alias
UMLS CUI [1,1]
C1522541
UMLS CUI [1,2]
C0439102
treatment experienced (prior sofosbuvir (sof) breakthrough/non-responder or prior sof relapser to sof/pegifn/rbv or sof/rbv)
Description

Therapy Received | sofosbuvir | PEGINTERFERON | Ribavirin | Breakthrough | Therapy non-responder | Relapse

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1514756
UMLS CUI [2]
C2976303
UMLS CUI [3]
C0982327
UMLS CUI [4]
C0035525
UMLS CUI [5]
C3666010
UMLS CUI [6]
C0919875
UMLS CUI [7]
C0035020
subject has plasma hcv rna > 1000 iu/ml at screening
Description

Plasma Hepatitis C virus RNA assay

Data type

boolean

Alias
UMLS CUI [1,1]
C0032105
UMLS CUI [1,2]
C1272251
chronic hcv genotype 4 infection with cirrhosis
Description

Chronic Hepatitis C Genotype | Liver Cirrhosis

Data type

boolean

Alias
UMLS CUI [1,1]
C0524910
UMLS CUI [1,2]
C1533728
UMLS CUI [2]
C0023890
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
positive test result at screening for hepatitis b surface antigen (hbsag) or anti-human immunodeficiency virus antibody (hiv ab).
Description

Hepatitis B surface antigen positive | HIV antibody positive

Data type

boolean

Alias
UMLS CUI [1]
C0149709
UMLS CUI [2]
C0920548
current enrollment in another interventional clinical study, previous enrollment in this study, or previous use of any protease inhibitor, non-nucleoside polymerase inhibitor, or nonstructural viral protein (ns) 5a inhibitor, either investigational or commercially available (including previous exposure to abt-450 or ombitasvir), or receipt of any investigational product within 6 weeks prior to study drug administration. prior use of any direct-acting antiviral will not be allowed, except for arm d where prior experience with the nucleoside polymerase inhibitor, sofosbuvir with pegifn/rbv or sof with rbv is required.
Description

Study Subject Participation Status | Interventional Study | Protease Inhibitors | Other Coding | Hepatitis C Virus NS5A Inhibitor | Exposure to ABT-450 | Exposure to Ombitasvir | Investigational New Drugs | DIRECT ACTING ANTIVIRALS

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C3274035
UMLS CUI [3]
C0033607
UMLS CUI [4]
C3846158
UMLS CUI [5]
C3883357
UMLS CUI [6,1]
C0332157
UMLS CUI [6,2]
C3712108
UMLS CUI [7,1]
C0332157
UMLS CUI [7,2]
C3852670
UMLS CUI [8]
C0013230
UMLS CUI [9]
C3653501
any current or past clinical evidence of child-pugh b or c classification or clinical history of liver decompensation including ascites, variceal bleeding, or hepatic encephalopathy.
Description

Child-Pugh Classification | Hepatic decompensation | Ascites | Bleeding varices | Hepatic Encephalopathy

Data type

boolean

Alias
UMLS CUI [1]
C4050412
UMLS CUI [2]
C1394798
UMLS CUI [3]
C0003962
UMLS CUI [4]
C0333106
UMLS CUI [5]
C0019151
confirmed presence of hepatocellular carcinoma.
Description

Liver carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C2239176
any cause of liver disease other than chronic hcv infection.
Description

Liver disease | Cause Except Chronic Hepatitis C

Data type

boolean

Alias
UMLS CUI [1]
C0023895
UMLS CUI [2,1]
C0015127
UMLS CUI [2,2]
C0332300
UMLS CUI [2,3]
C0524910
abnormal laboratory tests.
Description

Laboratory test result abnormal

Data type

boolean

Alias
UMLS CUI [1]
C0438215

Similar models

Eligibility Hepatitis C Virus NCT02265237

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Inclusion criteria Quantity Fulfill
Item
subjects must meet one of the following:
boolean
C1512693 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,3])
Therapy naive | Antiviral Therapy Absent Hepatitis C | Protocol Arm Roman letter
Item
treatment-naive (subject has never received antiviral treatment for hepatitis c infection) or for arms a, b, and c:
boolean
C0919936 (UMLS CUI [1])
C0280274 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0019196 (UMLS CUI [2,3])
C1522541 (UMLS CUI [3,1])
C0439102 (UMLS CUI [3,2])
Therapy Received | Interferon | Ribavirin | Therapy non-responder | Partial responder to therapy | Relapse
Item
treatment experienced (prior null responders, partial responders or relapsers to ifn/rbv)
boolean
C0087111 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C3652465 (UMLS CUI [2])
C0035525 (UMLS CUI [3])
C0919875 (UMLS CUI [4])
C1740822 (UMLS CUI [5])
C0035020 (UMLS CUI [6])
Protocol Arm Roman letter
Item
for arm d:
boolean
C1522541 (UMLS CUI [1,1])
C0439102 (UMLS CUI [1,2])
Therapy Received | sofosbuvir | PEGINTERFERON | Ribavirin | Breakthrough | Therapy non-responder | Relapse
Item
treatment experienced (prior sofosbuvir (sof) breakthrough/non-responder or prior sof relapser to sof/pegifn/rbv or sof/rbv)
boolean
C0087111 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C2976303 (UMLS CUI [2])
C0982327 (UMLS CUI [3])
C0035525 (UMLS CUI [4])
C3666010 (UMLS CUI [5])
C0919875 (UMLS CUI [6])
C0035020 (UMLS CUI [7])
Plasma Hepatitis C virus RNA assay
Item
subject has plasma hcv rna > 1000 iu/ml at screening
boolean
C0032105 (UMLS CUI [1,1])
C1272251 (UMLS CUI [1,2])
Chronic Hepatitis C Genotype | Liver Cirrhosis
Item
chronic hcv genotype 4 infection with cirrhosis
boolean
C0524910 (UMLS CUI [1,1])
C1533728 (UMLS CUI [1,2])
C0023890 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Hepatitis B surface antigen positive | HIV antibody positive
Item
positive test result at screening for hepatitis b surface antigen (hbsag) or anti-human immunodeficiency virus antibody (hiv ab).
boolean
C0149709 (UMLS CUI [1])
C0920548 (UMLS CUI [2])
Study Subject Participation Status | Interventional Study | Protease Inhibitors | Other Coding | Hepatitis C Virus NS5A Inhibitor | Exposure to ABT-450 | Exposure to Ombitasvir | Investigational New Drugs | DIRECT ACTING ANTIVIRALS
Item
current enrollment in another interventional clinical study, previous enrollment in this study, or previous use of any protease inhibitor, non-nucleoside polymerase inhibitor, or nonstructural viral protein (ns) 5a inhibitor, either investigational or commercially available (including previous exposure to abt-450 or ombitasvir), or receipt of any investigational product within 6 weeks prior to study drug administration. prior use of any direct-acting antiviral will not be allowed, except for arm d where prior experience with the nucleoside polymerase inhibitor, sofosbuvir with pegifn/rbv or sof with rbv is required.
boolean
C2348568 (UMLS CUI [1])
C3274035 (UMLS CUI [2])
C0033607 (UMLS CUI [3])
C3846158 (UMLS CUI [4])
C3883357 (UMLS CUI [5])
C0332157 (UMLS CUI [6,1])
C3712108 (UMLS CUI [6,2])
C0332157 (UMLS CUI [7,1])
C3852670 (UMLS CUI [7,2])
C0013230 (UMLS CUI [8])
C3653501 (UMLS CUI [9])
Child-Pugh Classification | Hepatic decompensation | Ascites | Bleeding varices | Hepatic Encephalopathy
Item
any current or past clinical evidence of child-pugh b or c classification or clinical history of liver decompensation including ascites, variceal bleeding, or hepatic encephalopathy.
boolean
C4050412 (UMLS CUI [1])
C1394798 (UMLS CUI [2])
C0003962 (UMLS CUI [3])
C0333106 (UMLS CUI [4])
C0019151 (UMLS CUI [5])
Liver carcinoma
Item
confirmed presence of hepatocellular carcinoma.
boolean
C2239176 (UMLS CUI [1])
Liver disease | Cause Except Chronic Hepatitis C
Item
any cause of liver disease other than chronic hcv infection.
boolean
C0023895 (UMLS CUI [1])
C0015127 (UMLS CUI [2,1])
C0332300 (UMLS CUI [2,2])
C0524910 (UMLS CUI [2,3])
Laboratory test result abnormal
Item
abnormal laboratory tests.
boolean
C0438215 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial